EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Multizentrische Studie

Combination of PD-1 blockade and neoadjuvant chemoradiotherapy benefits pMMR/MSS patients with locally advance rectal cancer: A phase 2 clinical trial

Zhengyang Yang, Zhuan Xu, Liting Sun, Jianyong Zheng, Jiagang Han, Ang Li, Gang Liu, Yi Sun, Jie Zhang, Guangyong Chen, Rui Xu, Chao Zhang und 5 weitere

Drug Resistance Updates · 2026

DOI: 10.1016/j.drup.2026.101384 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Drug Resistance Updates, 2026. Verfasst von Zhengyang Yang und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Surgery, Beijing Friendship Hospital, Capital Medical University & National Clinical Research Center for Digestive Diseases, Be…. Hauptthemen laut MEDLINE: Rectal Neoplasms, Neoadjuvant Therapy, Immune Checkpoint Inhibitors, Antibodies, Monoclonal, Humanized. Die Arbeit nennt 36 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

For patients with mismatch repair-proficient / microsatellite stable (pMMR/MSS) locally advanced rectal cancer (LARC), the NECTAR (NEoadjuvant Chemoradiotherapy plus immunoTherapy for locally Advanced Rectal cancer) trial reported an encouraging pathological complete response (pCR) rate of 40.0%. Given that pMMR/MSS tumors are generally resistant to immunotherapy, this pCR rate highlights the potential of combination therapy to overcome primary resistance. Here, we report the 3-year survival outcomes of the NECTAR trial, using neoadjuvant chemoradiotherapy (NCRT) plus tislelizumab in pMMR/MSS LARC. In this phase 2, multi-center, single-arm trial, eligible pMMR/MSS LARC patients received three cycles of neoadjuvant programmed cell death protein 1 (PD-1) blockade, three cycles of chemotherapy, and long-course radiotherapy followed by total mesorectal excision (TME). This 3-year analysis evaluates disease-free survival (DFS) and safety. From June 2021 to November 2022, 50 patients were enrolled and 46 patients completed neoadjuvant therapy and TME. Of the 46 patients, 20 patients reached pCR. With a median follow-up of 44.2 months, the median DFS was not reached. The 3-year DFS rate was 89.1%. All patients who achieved pCR (20/46) remained DFS at 3 years. Patients with a low neoadjuvant rectal (NAR) score (

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Rectal NeoplasmsNeoadjuvant TherapyImmune Checkpoint InhibitorsAntibodies, Monoclonal, HumanizedChemoradiotherapyHumansPathologic Complete ResponseFemaleMaleMiddle AgedDNA Mismatch RepairProgrammed Cell Death 1 ReceptorAgedDisease-Free SurvivalAdult

Stichwörter der Autor:innen

Disease-free survivalLocally advanced rectal cancerLong-term outcomesNeoadjuvantTislelizumab

Substanzen

Programmed Cell Death 1 ReceptortislelizumabImmune Checkpoint InhibitorsAntibodies, Monoclonal, HumanizedPDCD1 protein, human

Autor:innen und Institutionen

  • Department of General Surgery, Beijing Friendship Hospital, Capital Medical University & National Clinical Research Center for Digestive Diseases, Beijing, China.
  • Department of Gastrointestinal Surgery, The First Affiliated Hospital of Air Force Medical University, Xi'an, China.
  • Department of General Surgery, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China.
  • Department of General Surgery, Beijing Xuanwu Hospital, Capital Medical University, Beijing, China.
  • Department of General Surgery, Tianjin Medical University General Hospital, Tianjin, China.
  • Department of Anorectal, Tianjin People's Hospital, Tianjin, China.

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Yang, Z., Xu, Z., Sun, L., Zheng, J., Han, J., Li, A., Liu, G., Sun, Y., Zhang, J., Chen, G., Xu, R., Zhang, C., Gao, J., Bai, Z., Deng, W., Yao, H., & Zhang, Z. (2026). Combination of PD-1 blockade and neoadjuvant chemoradiotherapy benefits pMMR/MSS patients with locally advance rectal cancer: A phase 2 clinical trial. Drug Resistance Updates. https://doi.org/10.1016/j.drup.2026.101384

Vancouver

Yang Z, Xu Z, Sun L, Zheng J, Han J, Li A, et al. Combination of PD-1 blockade and neoadjuvant chemoradiotherapy benefits pMMR/MSS patients with locally advance rectal cancer: A phase 2 clinical trial. Drug Resistance Updates. 2026. doi:10.1016/j.drup.2026.101384

BibTeX
@article{Yang2026,
  author = {Yang, Zhengyang and Xu, Zhuan and Sun, Liting and Zheng, Jianyong and Han, Jiagang and Li, Ang and Liu, Gang and Sun, Yi and Zhang, Jie and Chen, Guangyong and Xu, Rui and Zhang, Chao and Gao, Jiale and Bai, Zhigang and Deng, Wei and Yao, Hongwei and Zhang, Zhongtao},
  title = {Combination of PD-1 blockade and neoadjuvant chemoradiotherapy benefits pMMR/MSS patients with locally advance rectal cancer: A phase 2 clinical trial},
  journal = {Drug Resistance Updates},
  year = {2026},
  doi = {10.1016/j.drup.2026.101384}
}
Kostenlos starten →